methyl 3-(3-bromopropoxy)-4-iodobenzoate | 1427219-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(3-bromopropoxy)-4-iodobenzoate
• CAS: 1427219-34-8
• 化学式: C₁₁H₁₂BrIO₃
• 分子量: 399.023
• InChiKey: LURXANMMLKTRTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-(3-bromopropoxy)-4-iodobenzoate 在 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Nickel-Mediated Inter- and Intramolecular C–S Coupling of Thiols and Thioacetates with Aryl Iodides at Room Temperature

  摘要：

  A Ni(0)-catalyzed intermolecular cross-coupling of various functionalized thiols and aryl Iodides has been developed and successfully extended to less explored intramolecular versions, where thioacetates could also be utilized as the strategic surrogate. Air-stable precatalysts, very mild conditions, and an easy protocol allow rapid access to medicinally useful aryl thioethers, as demonstrated in the facile synthesis of (+/-)-chuangxinmycin as a key step.

  DOI：

  10.1021/ol303366u
• 作为产物：
  描述：

  1,3-二溴丙烷 、 3-羟基-4-碘苯甲酸甲酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 0.5h， 生成 methyl 3-(3-bromopropoxy)-4-iodobenzoate
  参考文献：
  名称：

  Nickel-Mediated Inter- and Intramolecular C–S Coupling of Thiols and Thioacetates with Aryl Iodides at Room Temperature

  摘要：

  A Ni(0)-catalyzed intermolecular cross-coupling of various functionalized thiols and aryl Iodides has been developed and successfully extended to less explored intramolecular versions, where thioacetates could also be utilized as the strategic surrogate. Air-stable precatalysts, very mild conditions, and an easy protocol allow rapid access to medicinally useful aryl thioethers, as demonstrated in the facile synthesis of (+/-)-chuangxinmycin as a key step.

  DOI：

  10.1021/ol303366u

文献信息

• Methods of treating TTR amyloidosis using AG10
  申请人：EIDOS THERAPEUTICS, INC.

  公开号：US11058668B2

  公开（公告）日：2021-07-13

  Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

  本文描述了治疗受试者转甲状腺素（TTR）淀粉样变性的方法。这些方法包括在治疗受试者方面疗效显著且受试者耐受性良好的特定给药方案。
• Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis
  作者：Mark Miller、Arindom Pal、Wabel Albusairi、Hyun Joo、Beverly Pappas、Md Tariqul Haque Tuhin、Dengpan Liang、Raghavendra Jampala、Fang Liu、Jared Khan、Marjon Faaij、Miki Park、William Chan、Isabella Graef、Robert Zamboni、Neil Kumar、Jonathan Fox、Uma Sinha、Mamoun Alhamadsheh

  DOI：10.1021/acs.jmedchem.8b00817

  日期：2018.9.13

  Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies. While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease. A comparison of potency for leading TTR stabilizers in clinic and structural features important for effective TTR stabilization is lacking. Here, we found that molecular interactions reflected in better binding enthalpy may be critical for development of TTR stabilizers with improved potency and selectivity. Our studies provide mechanistic insights into the unique binding mode of the TTR stabilizer, AG10, which could be attributed to mimicking the stabilizing T119M variant. Because of the lack of animal models for ATTR-CM, we developed an in vivo system in dogs which proved appropriate for assessing the pharmacokinetics-pharmacodynamics profile of TTR stabilizers. In addition to stabilizing TTR, we hypothesize that optimizing the binding enthalpy could have implications for designing therapeutic agents for other amyloid diseases.
• METHODS OF TREATING TTR AMYLOIDOSIS USING AG10
  申请人：Eidos Therapeutics, Inc.

  公开号：EP3768841A1

  公开（公告）日：2021-01-27
• [EN] METHODS OF TREATING TTR AMYLOIDOSIS USING AG10<br/>[FR] MÉTHODES DE TRAITEMENT DE L'AMYLOSE TTR À L'AIDE D'AG10
  申请人：EIDOS THERAPEUTICS INC

  公开号：WO2019183463A1

  公开（公告）日：2019-09-26

  Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.